US92731L1061 - Common Stock
VINC stock results show that Vincerx Pharma missed analyst estimates for earnings per share the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vincerx Pharma (NASDAQ:VINC) just reported results for the first quarter of 202...
Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236,...
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced the pricing of an underwritten public offering...
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced a proposed underwritten public offering of...
Laser Photonics stock is rising higher on Tuesday as LASE investors celebrate a new unit order from L3Harris Technologies.
Vivos Therapeutics stock is up on Tuesday as VVOS investors react to the company securing full Medicare reimbursement for its OSA device.
Vincerx Pharma stock is falling hard on Tuesday after the company failed to impress VINC shareholders with its latest clinical trial update.
Pre-market stock movers are worth checking out as we get into all of the hottest news investors need to know about on Tuesday morning!
VIP236 demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with...
VINC stock results show that Vincerx Pharma beat analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vincerx Pharma (NASDAQ:VINC) just reported results for the fourth quarter of 20...
VIP236, first-in-class small molecule-drug conjugate (SMDC), preliminary Phase 1 data and update on pipeline progress will be presented by management at a...
Management to host virtual investor event on April 8 to highlight preliminary Phase 1 Data for VIP236, our first-in-class small molecule-drug conjugate (SMDC)
Management to host virtual investor event on April 8 to highlight preliminary Phase 1 Data for VIP236, our first-in-class small molecule-drug conjugate...